Logo Image
|Podcasts|May 9, 2019

Episode 31: Ruling in Favor of Biotech

Editor-in-Chief Lisa Henderson speaks with Bill Newell, CEO of Sutro Bipharma about his background in corporate law and how it helps him in his role as a biotech executive, the importance of collaboration between big pharma and biotech, a story about keeping the San Francisco Giants in the Bay area, and other analogies around sports related to running a biotech.

Editor-in-Chief Lisa Henderson speaks with Bill Newell, CEO of Sutro Biopharma about his background in corporate law and how it helps him in his role as a biotech executive, the importance of collaboration between big pharma and biotech, a story about keeping the San Francisco Giants in the Bay area, and other analogies around sports related to running a biotech.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

 

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Pharmaceutical Executive daily
Pharmaceutical Executive Daily: FDA Approves New Indication for Kerendia
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Read more
Pharmaceutical executive daily
Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.
Read more